Effects of suramin on human lung cancer cell lines.

[1]  J. Sambrook,et al.  Molecular Cloning: A Laboratory Manual , 2001 .

[2]  G. Giaccone,et al.  Using the techniques of molecular biology to search for novel insecticides. , 1993, Environmental health perspectives.

[3]  M. Spang‐Thomsen,et al.  Expression of transforming growth factor beta (TGF beta) receptors and expression of TGF beta 1, TGF beta 2 and TGF beta 3 in human small cell lung cancer cell lines. , 1993, British Journal of Cancer.

[4]  J. Heimans,et al.  Suramin: rapid loading and weekly maintenance regimens for cancer patients. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  G. Peters,et al.  The effect of schedule, protein binding and growth factors on the activity of suramin , 1992, International journal of cancer.

[6]  N. Zini,et al.  Monoclonal antibodies to human DNA topoisomerase I and the two isoforms of DNA topoisomerase II: 170- and 180-kDa isozymes. , 1992, Experimental cell research.

[7]  N. Zini,et al.  The 180-kDa isoform of topoisomerase II is localized in the nucleolus and belongs to the structural elements of the nucleolar remnant. , 1992, Experimental cell research.

[8]  H. Poulsen,et al.  Expression of the epidermal growth factor receptor in human small cell lung cancer cell lines. , 1992, Cancer research.

[9]  J. Foekens,et al.  Pleiotropic actions of suramin on the proliferation of human breast‐cancer cells in vitro , 1992, International journal of cancer.

[10]  J. Battey,et al.  Neuromedin B is present in lung cancer cell lines. , 1992, Cancer research.

[11]  N. Bleehen,et al.  Expression of insulinlike growth factor (IGF) and IGF-binding protein genes in human lung tumor cell lines. , 1992, Journal of the National Cancer Institute.

[12]  L. Helman,et al.  Suramin inhibits the growth of human rhabdomyosarcoma by interrupting the insulin-like growth factor II autocrine growth loop. , 1992, Cancer research.

[13]  C. Taylor,et al.  Effects of suramin on in vitro growth of fresh human tumors. , 1992, Journal of the National Cancer Institute.

[14]  G. Giaccone,et al.  Multidrug sensitivity phenotype of human lung cancer cells associated with topoisomerase II expression. , 1992, Cancer research.

[15]  K. Robbins,et al.  Suramin, an experimental chemotherapeutic drug, activates the receptor for epidermal growth factor and promotes growth of certain malignant cells. , 1992, The Journal of clinical investigation.

[16]  S. Bruno,et al.  Cell cycle dependent expression and stability of the nuclear protein detected by Ki‐67 antibody in HL‐60 cells , 1992, Cell proliferation.

[17]  G. Wilding,et al.  Disruption of cellular energy balance by suramin in intact human prostatic carcinoma cells, a likely antiproliferative mechanism. , 1991, Cancer research.

[18]  R. Kiss,et al.  Influence of suramin alone or in combination with DHT and PDGF on the cell proliferation of benign and malignant human prostatic tissues in organ cultures. , 1991, Anticancer research.

[19]  J. Kim,et al.  Inhibition of prostatic tumor cell proliferation by suramin: alterations in TGF alpha-mediated autocrine growth regulation and cell cycle distribution. , 1991, The Journal of urology.

[20]  G. Peters,et al.  Comparison of the sulforhodamine B protein and tetrazolium (MTT) assays for in vitro chemosensitivity testing. , 1991, European journal of cancer.

[21]  G. Nicolson,et al.  Suramin. A potent inhibitor of melanoma heparanase and invasion. , 1991, The Journal of biological chemistry.

[22]  C. Anderson,et al.  Suramin affects DNA synthesis in HeLa cells by inhibition of DNA polymerases. , 1990, Cancer research.

[23]  R. Kopp,et al.  Suramin alters phosphoinositide synthesis and inhibits growth factor receptor binding in HT-29 cells. , 1990, Cancer research.

[24]  M. Fischer,et al.  Location and characterization of the suramin binding sites of human serum albumin. , 1990, Biochemical pharmacology.

[25]  E. Kohn,et al.  Suramin inhibits laminin- and thrombospondin-mediated melanoma cell adhesion and migration and binding of these adhesive proteins to sulfatide. , 1990, Cancer research.

[26]  M. Pollak,et al.  Suramin blockade of insulinlike growth factor I-stimulated proliferation of human osteosarcoma cells. , 1990, Journal of the National Cancer Institute.

[27]  G. Mills,et al.  Suramin prevents binding of interleukin 2 to its cell surface receptor: a possible mechanism for immunosuppression. , 1990, Cancer research.

[28]  S. de Jong,et al.  Reduced DNA topoisomerase II activity and drug-induced DNA cleavage activity in an adriamycin-resistant human small cell lung carcinoma cell line. , 1990, Cancer research.

[29]  C. Hensey,et al.  Suramin, an anti‐cancer drug, inhibits protein kinase C and induces differentiation in neuroblastoma cell clone NB2A , 1989, FEBS letters.

[30]  C. Cornelisse,et al.  Nuclear distribution of the Ki-67 antigen during the cell cycle: comparison with growth fraction in human breast cancer cells. , 1989, Cancer research.

[31]  W. Earnshaw,et al.  Differential expression of DNA topoisomerases I and II during the eukaryotic cell cycle. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[32]  R. Coffey,et al.  Suramin inhibition of growth factor receptor binding and mitogenicity in AKR‐2B cells , 1987, Journal of cellular physiology.

[33]  R. Redfield,et al.  Clinical Pharmacokinetics of Suramin in Patients With HTLV‐III/LAV Infection , 1986, Journal of clinical pharmacology.

[34]  J. Minna,et al.  Growth of human small cell (oat cell) carcinoma of the lung in serum-free growth factor-supplemented medium. , 1980, Cancer research.

[35]  E. Clercq.  Suramin: A potent inhibitor of the reverse transcriptase of RNA tumor viruses , 1979 .

[36]  J A TAIANA,et al.  [Cancer of the lung]. , 1952, The Journal of the International College of Surgeons.

[37]  R. Stahel,et al.  In vitro effect of suramin on lung tumour cells. , 1993, European journal of cancer.

[38]  J. Fontana,et al.  Suramin, an active nonhormonal cytotoxic drug for treatment of prostate cancer: compelling reasons for testing in patients with hormone-refractory breast cancer. , 1992, Journal of the National Cancer Institute.

[39]  G. Milano,et al.  Epidermal growth factor receptor expression and suramin cytotoxicity in vitro. , 1990, European journal of cancer.

[40]  M. Hosang.  Suramin binds to platelet‐derived growth factor and inhibits its biological activity , 1985, Journal of cellular biochemistry.

[41]  John D. Minna,et al.  Bombesin-like peptides can function as autocrine growth factors in human small-cell lung cancer , 1985, Nature.

[42]  V. Devita,et al.  Cancer : Principles and Practice of Oncology , 1982 .

[43]  F. Hawking.  Suramin: with special reference to onchocerciasis. , 1978, Advances in pharmacology and chemotherapy.